Drug Profile
NB 01
Alternative Names: DA-9801; NB-01Latest Information Update: 08 Aug 2023
Price :
$50
*
At a glance
- Originator Dong-A Pharmaceutical
- Developer NeuroBo Pharmaceuticals
- Class Neuroprotectants; Phytotherapies
- Mechanism of Action Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Diabetic neuropathies
Most Recent Events
- 02 Aug 2023 NB 01 licensed to MThera Pharma worldwide for the treatment of Diabetic neuropathy
- 25 Apr 2023 NB 01 is available for licensing as of 25 Apr 2023. https://www.sec.gov/ix?doc=/Archives/edgar/data/1638287/000155837023005127/nrbo-20221231x10k.htm
- 31 Dec 2022 NeuroBo Pharmaceuticals has patent protection for NB 01 in USA, Brazil, Canada, China, the European Patent Convention, India, Japan, Mexico, the Republic of Korea, and Russia